Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens

• Published in: Patterns (New York, N.Y.) Vol. 1; no. 5; p. 100065
• Main Authors: Ayestaran, Iñigo, Galhoz, Ana, Spiegel, Elmar, Sidders, Ben, Dry, Jonathan R., Dondelinger, Frank, Bender, Andreas, McDermott, Ultan, Iorio, Francesco, Menden, Michael P.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 14-08-2020; Elsevier
• Subjects: biomarker discovery; biostatistics; cancer; cancer cell lines; CRISPR; drug combinations; drug high-throughput screens; drug resistance; early drug discovery; precision medicine; biostatistics; early drug discovery; CRISPR; drug high-throughput screens; DSML 5: Mainstream: Data science output is well understood and (nearly) universally adopted; precision medicine; cancer; drug resistance; cancer cell lines; biomarker discovery; drug combinations
• ISSN: 2666-3899; 2666-3899
• DOI: 10.1016/j.patter.2020.100065

High-throughput drug screens in cancer cell lines test compounds at low concentrations, thereby enabling the identification of drug-sensitivity biomarkers, while resistance biomarkers remain underexplored. Dissecting meaningful drug responses at high concentrations is challenging due to cytotoxicity, i.e., off-target effects, thus limiting resistance biomarker discovery to frequently mutated cancer genes. To address this, we interrogate subpopulations carrying sensitivity biomarkers and consecutively investigate unexpectedly resistant (UNRES) cell lines for unique genetic alterations that may drive resistance. By analyzing the GDSC and CTRP datasets, we find 53 and 35 UNRES cases, respectively. For 24 and 28 of them, we highlight putative resistance biomarkers. We find clinically relevant cases such as EGFRT790M mutation in NCI-H1975 or PTEN loss in NCI-H1650 cells, in lung adenocarcinoma treated with EGFR inhibitors. Interrogating the underpinnings of drug resistance with publicly available CRISPR phenotypic assays assists in prioritizing resistance drivers, offering hypotheses for drug combinations.
[Display omitted]
•Presenting a strategy for identifying rare drug-resistance markers in cancer cells•Effectively stratifying drug resistance from cytotoxicity in pharmacology screens•Generating hypotheses for resistance mechanisms underlying certain biomarkers•CRISPR screens support resistance hypotheses and shed light on cancer vulnerabilities
Cancer drug resistance is the major challenge of modern oncology. Identifying resistance and its biomarkers will empower the next generation of precision medicines. High-throughput pharmacology screens in cancer cell lines have successfully identified drug-sensitivity biomarkers, but drug-resistance biomarkers are underexplored. Intrinsic drug-resistance events are often rare and experimentally indistinguishable from cytotoxicity or artifacts without prior knowledge. To address this, we investigate cell-line populations sensitized to a drug treatment (i.e., carrying established sensitivity biomarkers) and characterize those cell lines that do not respond as expected. We highlight unique genetic features harbored by these cell lines and confirm their linkage to drug resistance using CRISPR gene essentiality data. Our analysis and results pave the way for enhanced precision medicine, guide further CRISPR screens, and identify potential drug combinations to tackle resistance.
Identifying cancer drug resistance and its biomarkers will empower the next generation of anti-cancer medicines, tailoring treatments to individual patients. Detecting drug resistance in high-throughput pharmacology screens is experimentally challenging. We present a computational framework identifying rare intrinsically resistant cancer cell lines. Our observations provide hypotheses for associated drug-resistance biomarkers, which we validate with independent CRISPR essentiality screens. Our results pave the way for enhancing cancer precision medicine and effective drug combinations to overcome resistance.